Abstract
Using a real-time quantitative PCR assay, we identified two patients with EBV-related lymphoproliferative disorders at a very early stage. Both had received an unmanipulated bone marrow transplant with anti-thymocyte globulin for conditioning. To estimate virus-specific immunity, the frequencies of EBV-specific CD8+ T cells were measured using an enzyme-linked immunospot assay. The frequencies of EBV-specific CD8+ T cells of the two were 3.2 and 7.7%, respectively, which had possibly expanded in vivo. After withdrawing the immunosuppressive agents or administering donor lymphocytes transfusion, their symptoms regressed in parallel with the viral load. Bone Marrow Transplantation (2000) 26, 199–201.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gross TG, Steinbuch M, DeFor T et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome Bone Marrow Transplant 1999 23: 251–258
Kimura H, Morita M, Yabuta Y et al. Quantitative analysis of Epstein–Barr virus load by using a real-time PCR assay J Clin Microbiol 1999 37: 132–136
Kuzushima K, Nakamura S, Nakamura T et al. Increased frequency of antigen-specific CD8+ cytotoxic T lymphocytes infiltrating an Epstein–Barr virus-associated gastric carcinoma J Clin Invest 1999 104: 163–171
Lucas KG, Burton RL, Zimmerman SE et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation Blood 1998 91: 3654–3661
Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein–Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation New Engl J Med 1994 330: 1185–1191
Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients Blood 1998 92: 1549–1555
Heslop HE, Li C, Krance RA et al. Epstein–Barr infection after bone marrow transplantation Blood 1994 83: 1706–1708
Khatri VP, Baiocchi RA, Peng R et al. Endogenous CD8+ T cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder J Immunol 1999 163: 500–506
Rees L, Thomas A, Amlot PL . Disappearance of an Epstein–Barr virus-positive post-transplant plasmacytoma with reduction of immunosuppression Lancet 1998 352: 789
Hoshino Y, Morishima T, Kimura H et al. Antigen-driven expansion and contraction of CD8+-activated T cells in primary EBV infection J Immunol 1999 163: 5735–5740
Acknowledgements
This work was supported by a grant from Japan Society for the Promotion of Science (JSPS-RFTFL00703). We thank Dr Kazuyoshi Watanabe, Department of Pediatrics, Nagoya University School of Medicine, for helpful suggestions and advice.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hoshino, Y., Kimura, H., Kuzushima, K. et al. Early intervention in post-transplant lymphoproliferative disorders based on Epstein–Barr viral load. Bone Marrow Transplant 26, 199–201 (2000). https://doi.org/10.1038/sj.bmt.1702492
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702492
Keywords
This article is cited by
-
Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute
Bone Marrow Transplantation (2009)
-
Fatal outcome in a patient developing Epstein–Barr virus-associated lymphoproliferative disorder (EBV-LPD) without measurable disease
Bone Marrow Transplantation (2001)